NATCO signs Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced the signing of a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company, for the manufacture and commercia lization of the drug Baricitinib for Covid-19 indication in India. In line with the licensing agreement, Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India.

NATCO had earlier received an emergency use authorization for Baricitinib tablets, from Central Drugs Standard Control Organization (COSCO), for use in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.927 as compared to the previous close of Rs. 924.05. The total number of shares traded during the day was 16895 in over 942 trades.

The stock hit an intraday high of Rs. 934.5 and intraday low of 919.9. The net turnover during the day was Rs. 15665620.

Source : Equity Bulls

Keywords